Daily Sepsis Research Analysis
Three studies advance sepsis science across the bench-to-bedside spectrum: a triggerable antimicrobial polypeptide that selectively activates on bacterial membranes and improves survival in a sepsis model; a mechanistic study showing CPT1A-mediated suppression of ferroptosis alleviates sepsis-induced acute lung injury; and a trans-ancestral human genetic analysis implicating alternative complement pathway variants in susceptibility to bacteremia and sepsis.
Summary
Three studies advance sepsis science across the bench-to-bedside spectrum: a triggerable antimicrobial polypeptide that selectively activates on bacterial membranes and improves survival in a sepsis model; a mechanistic study showing CPT1A-mediated suppression of ferroptosis alleviates sepsis-induced acute lung injury; and a trans-ancestral human genetic analysis implicating alternative complement pathway variants in susceptibility to bacteremia and sepsis.
Research Themes
- Mechanism-guided therapeutics for sepsis (ferroptosis modulation, selective antimicrobials)
- Host susceptibility and complement genetics in bacteremia/sepsis
- Translational pipeline from molecular design to in vivo efficacy
Selected Articles
1. Bacterial Phospholipid-Inducible Helix-Transformable Antimicrobial Polypeptides.
The authors engineer a phosphatidylglycerol-triggered helix-transformable antimicrobial polypeptide (C6-10) that limits mammalian cell entry at baseline yet switches to a highly helical, bactericidal state upon bacterial membrane recognition. C6-10 showed low systemic toxicity and robust efficacy in bladder infection and sepsis models, highlighting a strategy to decouple efficacy from toxicity in systemic antimicrobial therapy.
Impact: Introduces a mechanistically novel, triggerable AMP that improves selectivity and demonstrates in vivo efficacy in a sepsis model, addressing longstanding toxicity barriers in systemic peptide therapeutics.
Clinical Implications: While preclinical, this design could enable safer systemic antimicrobial peptides for severe infections including sepsis. It informs scaffold optimization (helicity, hydrophobicity, PG affinity) to balance efficacy and host safety.
Key Findings
- C6-10 maintains moderate intrinsic helicity (38%), reducing mammalian cell penetration and mitochondrial damage.
- Phosphatidylglycerol binding increases C6-10 helicity to ~77%, unleashing strong antibacterial activity.
- Increasing C-terminal hydrophobicity raises helicity but also mammalian cytotoxicity, defining a selectivity trade-off.
- Intravenous C6-10 exhibited low organ toxicity and significant efficacy in both bladder infection and sepsis models.
Methodological Strengths
- Mechanistically grounded design linking membrane composition to peptide conformation and activity.
- Demonstrated in vivo efficacy with systemic dosing and organ toxicity assessment.
Limitations
- Preclinical work without human pharmacokinetic, resistance, or microbiome interaction data.
- Limited pathogen spectrum and head-to-head comparisons with standard-of-care antibiotics not reported.
Future Directions: Define pharmacokinetics/pharmacodynamics, resistance potential, and spectrum; optimize scaffold for IV use; progress to GLP toxicology and early-phase trials in severe infections.
The helical conformation of antimicrobial peptides (AMPs) exerts a dual effect: it enhances bactericidal activity while concurrently increasing cytotoxicity by facilitating penetration into mammalian cells, leading to organelle damage. Herein, we report a bacterial phospholipid-inducible, helix-transformable antimicrobial polypeptide (HT-AMP) for enhancing the antimicrobial selectivity. The HT-AMP, C6-10, which has a charge-to-backbone span of 10 σ-bonds, adopts a moderate intrinsic helicity of 38% due to side-chain charge repulsion. This restrained conformation significantly reduces AMP penetration into mammalian cells, thereby minimizing mitochondrial damage. C6-10 shows a high affinity for the bacterial phospholipid phosphatidylglycerol (PG). Upon PG recognition, the side-chain charge repulsion of C6-10 is reduced, and its helicity increases to ∼77%, exhibiting robust antibacterial activity. Further extending the hydrophobicity of the C-terminal group increases the helicity of polypeptides, leading to enhanced mammalian cellular internalization and mitochondrial damage. C6-10 demonstrated low toxicity toward organs following intravenous administration and exhibited significant antibacterial efficacy in both a bladder infection model and a sepsis model. Overall, this PG-triggered helix-transformable strategy provides an effective approach to improving the antibacterial selectivity of AMPs.
2. CPT1A overexpression alleviates sepsis-induced acute lung injury by inhibiting ferroptosis through the enhancement of ACSL4 succinylation: evidence from clinical samples, mouse models, and alveolar epithelial cells.
CPT1A levels are reduced in SI-ALI, and restoring CPT1A suppresses ferroptosis by enhancing ACSL4 succinylation, lowering ACSL4 abundance and injury. CPT1A overexpression mitigated lung pathology in CLP sepsis, positioning CPT1A–ACSL4 succinylation as a druggable axis in sepsis-induced lung injury.
Impact: Defines a specific post-translational modification mechanism (ACSL4 succinylation by CPT1A) that links cellular metabolism to ferroptosis control in SI-ALI, offering a precise intervention point.
Clinical Implications: Ferroptosis modulation via the CPT1A–ACSL4 axis could be leveraged to prevent or treat sepsis-induced lung injury; it supports development of small-molecule activators of CPT1A succinyltransferase activity or ACSL4-targeting approaches.
Key Findings
- CPT1A expression is downregulated in patient samples and in SI-ALI mouse and cell models.
- CPT1A overexpression enhances ACSL4 succinylation, reduces ACSL4 levels, and suppresses ferroptosis markers (e.g., MDA, ROS, Fe2+).
- ACSL4 overexpression reverses CPT1A-mediated ferroptosis suppression in vitro, indicating pathway specificity.
- In CLP mice, CPT1A overexpression alleviates lung pathology and ferroptosis activation.
Methodological Strengths
- Triangulation across clinical samples, in vivo CLP model, and in vitro assays.
- Mechanistic validation with co-IP and rescue experiments (ACSL4 overexpression).
Limitations
- Relies on genetic overexpression; lacks pharmacologic modulation or dose–response data.
- Sample sizes and effect sizes across clinical specimens are not reported in detail.
Future Directions: Develop pharmacologic tools to modulate CPT1A or ACSL4 succinylation; test efficacy in diverse sepsis phenotypes and co-morbidities; assess safety and target engagement biomarkers.
Sepsis-induced acute lung injury (SI-ALI) is strongly influenced by ferroptosis, a regulated cell death pathway. Carnitine palmitoyltransferase 1A (CPT1A), known for its lysine succinyltransferase activity, regulates succinylation but its function in ferroptosis and SI-ALI remains to be elucidated. This study aim to determine the influence of CPT1A on ferroptotic processes in SI-ALI and to reveal the key regulatory mechanisms involved. The SI-ALI model was generated in C57BL/6 mice via cecal ligation and puncture (CLP), while alveolar epithelial cells MLE-12 were treated with lipopolysaccharides (LPS) to mimic SI-ALI in vitro. Quantitative PCR and Western blotting were employed to evaluate CPT1A levels in peripheral venous blood samples from SI-ALI patients, as well as in both the mouse and cellular models of SI-ALI. Ferroptosis was evaluated by measuring malondialdehyde, glutathione, Fe 2+ levels, and reactive oxygen species fluorescence intensity. To elucidate the underlying mechanisms, co-immunoprecipitation (co-IP) and standard IP techniques were utilized. Our findings indicated that CPT1A was downregulated in SI-ALI. Overexpression of CPT1A inhibited ferroptosis in the in vitro SI-ALI model by enhancing ACSL4 succinylation, thereby reducing ACSL4 expression. Notably, overexpression of ACSL4 counteracted CPT1A-mediated ferroptosis suppression in vitro. Moreover, CPT1A overexpression ameliorated pulmonary pathology and suppressed ferroptosis activation in the lungs of SI-ALI mice. Collectively, the results indicate that CPT1A alleviated SI-ALI through the inhibition of ferroptosis by promoting ACSL4 succinylation, providing a novel theoretical foundation and potential therapeutic target for SI-ALI treatment.
3. Genetic Variation in the Alternative Complement Pathway Contributes to Individual Susceptibility to Bacteremia and Sepsis.
Leveraging >600,000 participants in the MVP, this trans-ancestral analysis identified 25 lead genic SNPs and multiple regulatory variants in alternative complement pathway genes associated with bacteremia/sepsis phenotypes. Signals centered on CFB, CFI, and C5a receptors (C5AR1/C5AR2), including a novel exonic variant in C5AR1.
Impact: Provides large-scale human genetic evidence implicating complement signaling in sepsis susceptibility, informing precision risk stratification and complement-targeted therapeutic development.
Clinical Implications: While not practice-changing yet, these findings motivate genotype-guided enrichment and response prediction in trials of complement-directed agents and may inform future risk prediction tools.
Key Findings
- Twenty-five lead genic SNPs (MAF >1%) associated with bacteremia/sepsis Phecodes in trans-ancestral MVP meta-analysis.
- Four exonic variants identified, including a novel C5AR1 variant (rs4804049) linked to multiple Phecodes.
- Fourteen regulatory SNPs predicted in silico and eleven eQTL-supported SNPs impacting AP gene expression, with signals in CFB, CFI, C5AR1/C5AR2, and CFD.
Methodological Strengths
- Very large sample size with trans-ancestral meta-analysis improving generalizability.
- Integration of eQTL and in silico regulatory annotations strengthens biological plausibility.
Limitations
- EHR-derived Phecodes may introduce misclassification; effect sizes and clinical utility remain to be quantified.
- Lacks independent prospective validation and functional mechanistic experiments.
Future Directions: Replicate in independent cohorts, perform functional validation of prioritized SNPs/genes, and test polygenic and pathway-based risk scores in prospective sepsis cohorts.
IMPORTANCE: The alternative complement pathway is a key component of host defense against bacteremia and other infections. However, dysregulated activation can contribute to excessive inflammation and worse clinical outcomes during bacteremia and infectious syndromes such as sepsis. OBJECTIVES: We aim to identify variants in alternative pathway (AP) genes that influence the risk for bacteremia and sepsis. DESIGN, SETTING, AND PARTICIPANTS: We used summary statistics from a Veterans Affairs Million Veteran Program (MVP) genome-wide by phenome-wide association study of more than 600,000 individuals. MAIN OUTCOMES AND MEASURES: Using seven electronic health record-derived Phecodes for bacteremia or sepsis, we investigated associations with single-nucleotide polymorphisms (SNPs) in genes encoding multiple AP components. We also investigated potential regulatory SNPs near candidate genes based on expression quantitative trait loci (eQTL) data or in silico modeling (Combined Annotation Dependent Depletion and RegulomeDB scores). RESULTS: In the MVP trans-ancestral meta-analysis, we identified 25 unique lead genic SNPs with a minor allele frequency of greater than 1% that were significantly associated with incidence of sepsis or bacteremia Phecodes. Most were intronic (n = 21), with four exonic variants, including one in C5AR1 (rs4804049) that has novel associations with multiple Phecodes. Outside of AP gene loci, we also identified significant associations in 14 unique SNPs with predicted regulatory effects by in silico modeling and 11 unique SNPs with eQTL data suggesting an impact on AP gene expression. Variants in complement factor B (CFB), complement factor I (CFI), and C5a receptors (C5AR1/C5AR2) accounted for most of the significant genic SNPs, while noncoding functional variants primarily affected CFB, CFD, and the C5a receptor 1 (C5AR1). CONCLUSIONS AND RELEVANCE: We identified potentially clinically relevant genetic variation in the alternative complement pathway that may contribute to individual susceptibility to bacteremia and sepsis syndromes. Further study is required to understand the mechanisms behind these associations and their clinical impacts.